Coronavirus company news summary – IQVIA supports J&J’s vaccine clinical trials – Moderna teams up with Baxter for vaccine manufacturing

Allie Nawrat 9 March 2021 (Last Updated March 9th, 2021 09:06)

9 March 2021

Abivax is stopping its miR-AGE Phase IIb/III clinical trial of high-risk Covid-19 patients. This came after the trial’s independent Data Safety and Monitoring Board (DSMB) found a lack of efficacy in interim analysis from 305 high-risk patients who had completed the study period. The data found lower than expected rate of progression to severe disease or death, with no difference in the severity rate in the drug or the placebo group.

IQVIA has been collaborating with Johnson & Johnson‘s Janssen Research & Development on Phase III Covid-19 vaccine clinical trials since September 2020. The studies use IQVIA’s suite of decentralised trial solutions for both on-site and remote study delivery through telehealth technologies, digital patient engagement, and virtual oversight strategies.

Baxter International and Moderna have entered into an agreement for the former’s Baxter BioPharma Solutions to provide fill and finish sterile manufacturing services, as well as supply packaging, for up to 90 million doses of the Moderna Covid-19 Vaccine in 2021 in the US. The vaccine will be manufactured at the BioPharma Solutions facilities in Bloomington, Indiana.